Amplified Mycobacterium Tuberculosis Direct Test (MTD Test)
by Gen-Probe
PMA P940034
Active
Valid until
No expiry
FDA recalls
None foundDocuments
Trust
Unverified
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA PMAAPRL | NumberP940034 | Date15 Dec 1995 | StatusActive |
Recalls
No FDA recalls found in the data synced 6 Oct 2026.
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA PMA Active
Specification
- Full name
- Gen-Probe(R) Amplified Mycobacterium Tuberculosis Direct Test (Mtd Test)
- Generic Name
- System, nucleic acid amplification, mycobacterium tuberculosis complex
- FDA applicant
- Gen-Probe, Inc.
- PMA Number
- FDA Product Code
- MWA
- Device Class
- Class II
- Regulation
- 21 CFR Part 866.3372
- Advisory Committee
- Microbiology
- FDA Decision
- APRL
Overview
AI-generated summary, 18 Sep 2026
The Amplified Mycobacterium Tuberculosis Direct Test (MTD Test) is a nucleic acid amplification system designed for the in vitro detection of Mycobacterium tuberculosis complex ribosomal RNA (rRNA) in clinical specimens. It functions as a molecular diagnostic tool to identify M. tuberculosis directly from acid-fast bacilli (AFB) smear-positive or negative concentrated sediments, including sputum or bronchial specimens.
This test is supplied as a single-use diagnostic device and is intended for use in microbiology laboratories. It requires amplification of target nucleic acid sequences for detection via hybridization probes, with results available more rapidly than traditional culture methods. The device is regulated under FDA Premarket Approval (PMA) and falls under Class II classification (MWA product code) for microbiology applications, adhering to strict in vitro diagnostic (IVD) standards.